BIOMAT Database Logo BIOMAT Database Logo

Production of monoclonal antibody against human prostatic adenocarcinoma and its immunohistochemical properties. 1990

H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Department of Urology, Nara Medical University, Japan.

We have generated a monoclonal antibody against prostatic adenocarcinoma, PC-Ab (IgM) was derived from a fusion using the fresh prostatic tissue of adenocarcinoma as the immunogen. Initial screening was performed by enzyme-linked immunosorbent assay (ELISA) on the soluble fraction of the immunogen. The specific analysis was performed by the avidin-biotin-complex immunoperoxidase method on paraffin-embedded sections of normal, benign and malignant neoplastic tissues from the prostate and various organs. PC-Ab reacted with well differentiated adenocarcinoma (83.3%), moderately differentiated adenocarcinoma (92.2%), and poorly differentiated adenocarcinoma (90.2%), respectively. According to classification by stage, the reaction rates with stage T0, T1, T2, T3 and T4 were 77.3%, 80.0%, 95.2%, 91.3% and 92.9%, respectively but no significant differences in the stages were seen among these groups. PC-Ab reacted with the epithelium of the normal prostate and benign prostatic adenoma, and human fetal tissues. Molecular weight and isoelectric point of the antigen recognized by this PC-Ab was estimated to be 57,000 daltons and 7.0, respectively. These results indicate that PC-Ab reacts with the antigen associated with human prostatic adenocarcinoma.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody

Related Publications

H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production of monoclonal antibody against amyloid fibril protein and its immunohistochemical application.
January 1985, Applied pathology,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
[Monoclonal antibody LC85a against human lung adenocarcinoma].
December 1985, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production and properties of a monoclonal antibody against human epidermal growth factor.
February 1985, Biochemistry international,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production of a monoclonal antibody (59.4) against canine lymphocyte surface antigen and its immunohistochemical application.
April 1997, The Journal of veterinary medical science,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production of monoclonal antibody against histamine and its application to immunohistochemical study in the stomach.
June 1998, The Histochemical journal,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Novel immunohistochemical monoclonal antibody against human XBP-1.
October 2010, Hybridoma (2005),
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production of Monoclonal Antibody against Human Nestin.
April 2010, Avicenna journal of medical biotechnology,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production of monoclonal antibody reactive with leukotoxin and its immunohistochemical application.
December 1994, Forensic science international,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
[Production of polyclonal antibody against human androgen receptor and immunohistochemical study of human androgen receptor in prostatic tissues].
November 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
H Matsuki, and S Ozono, and T Yoshie, and K Kubota, and Y Hirao, and N Konishi, and H Hashimoto, and M Ohshima, and Y Hiasa, and E Okajima
Production of a monoclonal antibody against human amelogenin.
January 1994, Calcified tissue international,
Copied contents to your clipboard!